51 Views | 43 Downloads
Harold E Bays, hbaysmd@outlook.com
HEB served as the medical writer and editor for all sections. The following authors primarily updated the following sections: PS (Nutrition), AI (Physical Inactivity), RD (Dyslipidemia), AT (Pre-diabetes/diabetes), MAR (High Blood Pressure), AM (Obesity), AT & YAS (Special Populations), CG (Thrombosis with smoking as a potential contributor to thrombosis), AN (Kidney Dysfunction), AK & SS (Family history/genetics/familial Hypercholesrerolemia), PPT reviewed and/or commented on all sections.
In the past 12 months, HEB's research site received research grants from 89Bio, Allergan, Alon Medtech/Epitomee, Amgen, Anji Pharma, AstraZeneca, Bionime, Boehringer Ingelheim, CinCor, Civi, Eli Lilly, Esperion, Evidera, Gan and Lee, Home Access, Lexicon, Matinas, Merck, Novartis, NovoNordisk, Pfizer, Regeneron, Sanofi, and TIMI. In the past 12 months, HEB has served as a consultant/advisor for 89Bio and Esperion, and speaker for Esperion and Novo Nordisk. PPT has served on the speaker's bureau of Amarin, Amgen, Esperion, Novo-Nordisk, Organon, and served as a consultant to Amarin, Amgen, Merck, Novartis, Resverlogix, and Theravance. RD reports serving as a consultant for Hims and Hers Health. AK, CG, PS, AI, AT, MAR, AM, AT, YA, AJN, and SS do not report relevant disclosures.
The development of this manuscript received no funding.
© 2022 The Authors. Published by Elsevier B.V.